Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MOXIFLOXACIN HYDROCHLORIDE

All products: general benefit

Other products in the same Health Canada class (J01MA) — coverage varies; not interchangeable

  • Ciprofloxacin (Cipro): general benefit, Limited Use 533, Not a benefit
  • Levofloxacin (Levaquin): general benefit, Not a benefit
  • Norfloxacin (Noroxin): general benefit, Not a benefit
  • Ciprofloxacin + ciprofloxacin base (Cipro XL): limited Use 394, Not a benefit

Jamp-Moxifloxacin · DIN 02443929 · 400mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Moxifloxacin · DIN 02443929 Manufacturer: Jamp Pharma Corporation; listing date 2015-12-22 Health Canada: Marketed since 2025-10-31 · brand JAMP-MOXIFLOXACIN · ATC J01MA14 MOXIFLOXACIN · form Tablet · route Oral · ingredients MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Moxifloxacin: Formulary list price $1.5230/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.5230 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92870 · Verify on the e-Formulary ↗ (DIN 02443929)

Source record
DIN 02443929: Jamp-Moxifloxacin Raw flags: sec3=Y Item: 084000053; group id 137; item number 0230; lccId None; manufacturer id JPC Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $1.5230; ministry $1.5230 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443929 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92870
Interchangeable products
AG-Moxifloxacin · DIN 02478137 · $1.5230 Apo-Moxifloxacin · DIN 02404923 · $1.5230 Auro-Moxifloxacin · DIN 02432242 · $1.5230 Avelox · DIN 02242965 · not recorded Jamp-Moxifloxacin Tablets · DIN 02447061 · $1.5230 M-Moxifloxacin · DIN 02472791 · $1.5230 Mar-Moxifloxacin · DIN 02447053 · $1.5230 Med-Moxifloxacin · DIN 02457814 · $1.5230 Moxifloxacin · DIN 02520710 · $1.5230 Sandoz Moxifloxacin · DIN 02383381 · $1.5230 Teva-Moxifloxacin · DIN 02375702 · $1.5230
Shortage status: resolved shortage (ended 2025-10-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443929
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

LINEZOLID

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: patients 1 year of age and older with bacterial conjunctivitis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. GATIFLOXACIN · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS ZYMAR® (gatifloxacin) is indicated for the treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of the following bacteria: Aerobic Gram-positive bacteria: • Staphylococcus aureus • Staphylococcus epidermidis • Streptococcus pneumoniae Aerobic Gram-negative bacteria: • Haemophilus influenzae To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYMAR and other antibacterial drugs, ZYMAR should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Pediatrics Pediatrics (≥ 1 year and ≤ 12 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of ZYMAR in pediatric patients 1 year of age and older has been established; therefore, Health Canada has authorized an indication for pediatric use. PM: https://pdf.hres.ca/dpd_pm/00067074.PDF; date AUG 30, 2004; DIN 02257270; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE VIGAMOX® (moxifloxacin ophthalmic solution) is indicated for the treatment of patients 1 year of age and older with bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic, Gram-Positive Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Streptococcus pneumoniae Streptococcus viridans group Aerobic, Gram-Negative Acinetobacter species Haemophilus influenza To reduce the development of the drug-resistant bacteria and maintain the effectiveness of VIGAMOX and other antibacterial drugs, VIGAMOX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. VIGAMOX® Product Monograph Page 3 of 27 Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed … https://pdf.hres.ca/dpd_pm/00042774.PDF PM date: December 1, 2017 Source product: VIGAMOX; DIN 02252260; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.